Pacific Biosciences of California (NASDAQ:PACB) Stock Price Up 7.3% – Time to Buy?

26 Oct 2026, 18:01 by Sarita Garza · The Markets Daily

Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) rose 7.3% during trading on Monday. The stock traded as high as $2.24 and last traded at $2.2650. 2,589,406 shares traded hands during mid-day trading, a decline of 68% from the average daily volume of 7,967,515 shares. The stock had previously closed at $2.11.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Weiss Ratings raised Pacific Biosciences of California from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, October 13th. Wall Street Zen lowered Pacific Biosciences of California from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, UBS Group began coverage on Pacific Biosciences of California in a report on Wednesday, September 9th. They issued a “neutral” rating and a $1.35 price target for the company. One investment analyst has rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus price target of $1.71.

View Our Latest Analysis on PACB

Pacific Biosciences of California Stock Performance

The firm has a 50 day moving average price of $1.69 and a two-hundred day moving average price of $1.53. The firm has a market capitalization of $700.92 million, a P/E ratio of -5.24 and a beta of 2.19.

Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The biotechnology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The firm had revenue of $39.01 million during the quarter, compared to analysts’ expectations of $42.90 million. Pacific Biosciences of California had a negative net margin of 82.49% and a negative return on equity of 5,752.12%. Equities research analysts forecast that Pacific Biosciences of California, Inc. will post -0.52 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Mark Van Oene sold 26,911 shares of Pacific Biosciences of California stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1.13, for a total transaction of $30,409.43. Following the completion of the sale, the insider directly owned 2,705,853 shares in the company, valued at $3,057,613.89. The trade was a 0.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James Gibson, II sold 661,815 shares of the firm’s stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $3.11, for a total value of $2,058,244.65. Following the completion of the sale, the insider directly owned 1,083,848 shares in the company, valued at $3,370,767.28. This trade represents a 37.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Hhlr Advisors LTD. acquired a new position in Pacific Biosciences of California in the second quarter valued at about $1,544,000. BlackRock Inc. acquired a new stake in shares of Pacific Biosciences of California during the second quarter worth $54,330,000. Bank of America Corp DE bought a new position in shares of Pacific Biosciences of California during the second quarter worth $2,265,000. Bank of New York Mellon Corp acquired a new position in shares of Pacific Biosciences of California in the 2nd quarter valued at approximately $1,290,000. Finally, Man Group plc acquired a new stake in shares of Pacific Biosciences of California during the second quarter worth $1,004,000.

Pacific Biosciences of California Company Profile

(Get Free Report)

Pacific Biosciences of California, Inc (NASDAQ: PACB) is a life sciences technology company that develops and supplies DNA sequencing systems, consumables and related software. The company is best known for its single-molecule, real-time (SMRT) sequencing technology, which produces highly accurate long-read data used to analyze complex genomes, structural variation, genetic disease and other biological information.